What Does Equivocal Test Result Mean?

An equivocal test result means the test could not clearly classify you as positive or negative. The result falls into a gray zone between the two, where the measurement is too close to the dividing line for the lab or clinician to confidently call it one way or the other. This is not a failure of the test or a sign that something went wrong during processing, though sample problems can sometimes be to blame. In many areas of medicine, equivocal results are a built-in reality of how diagnostic testing works, and they come with their own set of follow-up steps.

Why Tests Have a Gray Zone at All

Most medical tests work by measuring something in your body, whether it is an antibody level in your blood, the amount of a protein on a tumor cell, or the shape of cells under a microscope, and then comparing that measurement to a cutoff. Above the cutoff, the result is called positive; below it, negative. The problem is that biology does not always produce clean, dramatic differences between people who have a condition and people who do not. Many measurements overlap. A person who is perfectly healthy might produce a value just below the cutoff, and a person with early disease might produce a value just above it. When a result lands right near that boundary, forcing it into a simple yes-or-no answer introduces the risk of being wrong in either direction.

Researchers have formally proposed handling this by building a three-zone system for quantitative tests: positive, negative, and an intentional gray zone in between. The idea is to avoid the “black or white” binary that often does not match clinical reality.¹ In blood-donor screening, for example, a gray zone is explicitly defined for results that come close to the cutoff but fall just below it, triggering follow-up testing rather than an immediate rejection or clearance.² The labels vary by field: you might see “equivocal,” “indeterminate,” “inconclusive,” “borderline,” or “atypical.” They all point to roughly the same situation, though the specific follow-up steps differ depending on what is being tested.

Common Reasons a Result Lands in the Gray Zone

Sometimes the problem is biological. Your immune system might be in the early stages of responding to an infection, producing just enough antibodies to register on the test but not enough to clear the positive threshold. Some cancers express a protein at a middling level that does not match either the “clearly overexpressed” or “clearly normal” pattern the test is designed to sort. In other cases, your body’s immune state itself, such as being immunosuppressed, can dampen the signals a test relies on.

Other times the issue is technical. For tuberculosis blood tests, common problems include tubes that were underfilled or overfilled, tubes that got mixed up, and deviations in how long the sample sat before processing.³ In cytology, where pathologists examine cells under a microscope, equivocal results are more likely when the sample has low volume or very few cells to examine. A study of indeterminate diagnoses in fluid cytology found that low cellularity was a factor in the majority of unclear cases, and that more than one contributing problem was present nearly half the time.⁴

In practice, you cannot always tell which factor caused your specific equivocal result. That ambiguity is part of why doctors treat these results as requiring more investigation rather than more guesswork.

Equivocal Results in Infectious Disease Testing

Lyme disease testing is one of the best-known examples. The standard approach uses a two-step process: first a sensitive screening test, and then, if the result is positive or equivocal, a more specific confirmatory test called a Western blot.⁵ The equivocal screening result is treated the same as a positive one for the purpose of triggering that second step, because the whole point of the screening test is to cast a wide net. An equivocal Lyme screening test does not mean you probably have Lyme disease; it means the test could not rule it out, so the more specific test needs to weigh in.⁶

HIV confirmatory testing follows a similar pattern. When a screening test comes back indeterminate, the sample goes to a more detailed assay that looks at specific antibody patterns. One study comparing two confirmatory HIV assays found that when the first test produced indeterminate results, the second assay reclassified the vast majority as negative.⁷ That finding reflects what clinicians generally see: most equivocal infectious disease results in low-risk people turn out to be negative on follow-up. But “most” is not “all,” which is why the follow-up is not optional.

When Cancer Testing Returns an Equivocal Result

In breast cancer, one of the most consequential equivocal results involves HER2 testing. HER2 is a protein that, when overexpressed, drives aggressive tumor growth, but it also means the cancer can be treated with targeted drugs. The initial test uses a method called immunohistochemistry, which scores HER2 expression on a scale. A score of 0 or 1+ is considered negative, 3+ is positive, and 2+ is equivocal. That middle category accounts for roughly 15% of all breast tumors and is subject to significant variation between pathologists reading the same slides.⁸

The standard next step for equivocal HER2 results is a more precise test that counts actual copies of the HER2 gene. Guidelines from the American Society of Clinical Oncology and the College of American Pathologists recommend this reflex testing for all equivocal cases.⁹ One study found that using alternative methods to re-evaluate equivocal HER2 cases, about 61% were ultimately reclassified as positive, meaning the patients were eligible for HER2-targeted therapy.¹⁰ That is a high reclassification rate and underscores why equivocal does not mean unimportant; for many of these patients, the equivocal result is the step between them and a treatment that could save their lives.

However, the yield of follow-up testing depends on the tumor type. Among well-differentiated breast cancers, which tend to be slower-growing, the rate of HER2 amplification is very low. One study found that only about 0.3% of well-differentiated tumors that initially scored equivocal turned out to be truly HER2-amplified.⁹ This has prompted some researchers to question whether blanket reflex testing is always the right approach, especially in metastatic cases where selective testing with careful pathologist review might be sufficient.¹¹

Equivocal Cervical Screening and What Comes Next

If you have had a Pap smear come back as ASCUS, short for “atypical squamous cells of undetermined significance,” you have received what is essentially an equivocal cervical screening result. The cells looked somewhat abnormal under the microscope but not abnormal enough to be classified as a clear precancerous lesion.¹² ASCUS is quite common and, for most women, does not lead to a cancer diagnosis. But it is not something to ignore.

The usual follow-up is HPV testing. If the HPV test is negative, the risk of a serious underlying lesion is very low, and routine monitoring continues. If HPV is positive, especially for high-risk strains, closer follow-up or colposcopy may be recommended. Long-term data suggests that persistence of high-risk HPV can lead to progression of ASCUS findings even years later, which is why routine HPV testing is recommended for women with ASCUS results, particularly those with additional risk factors.¹³ The cost-effectiveness of different strategies for managing equivocal cervical results has been studied extensively. In one analysis, HPV triage for women over 30 was the most cost-effective approach, outperforming both repeat cytology alone and immediate colposcopy for everyone.¹⁴

How Equivocal Results Complicate Treatment Decisions

In prostate cancer, equivocal staging results are a recurring headache. Imaging might show something that could be a sign of cancer spreading beyond the prostate, or could be nothing at all. Research on this has found that isolated equivocal findings of spread are often prognostically meaningless by themselves, and they only start to matter when they pile up alongside clear evidence of extracapsular spread.¹⁵ In other words, a single fuzzy finding on a bone scan should not, on its own, change the treatment plan.

Treatment decisions get even more uncomfortable when both the estrogen receptor status and the HER2 status of a breast tumor are equivocal. These are the two main biomarkers that determine which drug classes a patient can benefit from. When both are borderline, oncologists face a genuine dilemma: do you give endocrine therapy, targeted HER2 therapy, both, or neither? Because a potentially life-saving benefit from empirical treatment cannot be excluded, some researchers argue the safest approach is to consider both therapies in this rare subset of patients.¹⁶ That is a lot of treatment burden carried by patients whose biology genuinely does not fit the categories we have built.

What Happens to Test Accuracy When Equivocal Results Are Thrown Out

One of the less obvious problems with equivocal results is what happens behind the scenes when researchers report how accurate a test is. When equivocal or unevaluable results are simply excluded from the analysis, the remaining numbers look artificially good. A study on CT urography demonstrated this clearly: excluding the roughly 15% of results that were inconclusive inflated the reported sensitivity and specificity to near-perfect levels, which would have led clinicians to trust the test more than they should.¹⁷

This matters because when you look at a test’s advertised accuracy, the numbers you see may not account for the cases where the test simply could not make up its mind. A meta-analysis of coronary CT angiography that explicitly included unevaluable results found that those ambiguous scans had an equivocal likelihood ratio well below 1.0, meaning they actually shifted the probability of disease downward slightly, but not enough to rule anything out. The test was most useful at intermediate pre-test probabilities.¹⁸ The practical takeaway is that your doctor’s assessment of how likely you were to have the condition before the test was ordered can be just as important as the test result itself, especially when that result is equivocal.

This concept, often called pre-test probability, shapes how much an equivocal result should change anyone’s thinking. If the clinical suspicion was already high, an equivocal result is more concerning than if the test was a routine screen in someone with no symptoms. In psychiatric risk assessment, researchers have found that patients with equivocal results on initial evaluation typically need at least two or three additional assessments before a meaningful risk classification emerges.¹⁹ One equivocal result rarely tells you much by itself; it is the accumulation of evidence that eventually tips the balance.

The Emotional Weight of Not Knowing

Clinicians are trained to treat equivocal results as a routine part of diagnostic workups. For patients, though, the experience can be genuinely distressing. You went in expecting an answer, positive or negative, and came out with neither. That uncertainty is not just philosophically uncomfortable; it has measurable psychological effects.

Research on women who received indeterminate prenatal ultrasound findings found that incomplete or unclear results were associated with significantly higher anxiety compared to normal results.²⁰ In genetic testing for BRCA1/2 mutations, inconclusive results have been linked to anxiety and distress, and the uncertainty can influence whether patients follow through with recommended surveillance or preventive measures.²¹ Some patients reduce their compliance with screening protocols after receiving an inconclusive genetic result, which is the opposite of what the medical situation calls for. Health professionals themselves feel frustrated by the limitations of current technology when explaining these results, recognizing that the tools available do not yet allow clear-cut predictions in every case.²²

This is an area where communication makes a real difference. Researchers studying the psychosocial impact of genetic counseling have specifically identified inconclusive test results as a key area needing better clinical attention.²³ If your doctor does not proactively explain what an equivocal result means and what the plan is going forward, asking is reasonable and warranted. The answer is almost never “we do nothing.” There is a next step, and knowing what it is tends to reduce the anxiety of the waiting period.

What You Should Do If You Get One

The single most important thing to understand about an equivocal result is that it is not a final answer. It is a waypoint. In nearly every clinical scenario, an equivocal result triggers a specific protocol: repeat the test, use a different and more specific test, wait a defined period and retest, or combine the result with other clinical information to decide the next move. In Lyme disease, the protocol is a Western blot. In breast cancer HER2 testing, it is gene-level analysis. In cervical screening, it is HPV testing. In HIV testing, it is a more detailed confirmatory assay. The follow-up is not discretionary; it is built into the testing guidelines.

What you should not do is treat an equivocal result as either reassuring or alarming on its own. The whole meaning of the word is that the test lacks the information to support either conclusion. If a doctor tells you your result is equivocal and does not mention next steps, ask. If you are told to “just watch and wait” without a defined timeline or repeat test, ask for specifics. The evidence consistently shows that equivocal results need resolution, not wishful thinking in either direction.

When Equivocal Might Actually Mean Low Risk

Context shapes how worried you should be. An equivocal HER2 result in a well-differentiated breast tumor has an extremely low chance of being reclassified as positive on follow-up, because that tumor type almost never overexpresses HER2. An equivocal Lyme screening test in someone who has never been to an area where Lyme disease is common, has no tick exposure history, and has no compatible symptoms is overwhelmingly likely to be a false alarm. An equivocal TB blood test in a young, healthy person who had the tube slightly underfilled may just reflect a sample-handling issue. Your clinical picture, your risk factors, and the specific test involved all feed into what the equivocal result actually means for you specifically.

Bayesian models, which are just formal ways of combining your prior risk with test results, have been built specifically to handle equivocal outcomes. In one modeling study of diagnostic testing for malignant hyperthermia susceptibility, a special case was constructed for equivocal results that accounted for pre-test probability and the test’s known accuracy rates.²⁴ The principle is the same in everyday medicine: the equivocal result does not exist in isolation. Your doctor has information the lab report does not, and combining the two is how a meaningful clinical decision gets made.

None of this makes the experience of receiving an equivocal result any less frustrating. But the frustration is a feature of honest medicine. A test that forces every borderline case into a definitive yes or no would feel cleaner, but it would be wrong more often, and in medicine, being wrong in either direction has real consequences. The gray zone exists because the alternative is worse.